These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23300854)

  • 1. A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
    Lee WY; Sun LM; Lin MC; Liang JA; Chang SN; Sung FC; Muo CH; Kao CH
    PLoS One; 2012; 7(12):e53032. PubMed ID: 23300854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC; Yang CY; Kao Yang YH; Lin SJ
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.
    Peng YL; Hu HY; Luo JC; Hou MC; Lin HC; Lee FY
    Osteoporos Int; 2014 May; 25(5):1617-23. PubMed ID: 24566586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
    Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
    Chiang CH; Huang CC; Chan WL; Huang PH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
    J Bone Miner Res; 2012 Sep; 27(9):1951-8. PubMed ID: 22532232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study.
    Sun LM; Lin MC; Muo CH; Liang JA; Kao CH
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4259-64. PubMed ID: 25144633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
    Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
    J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the alendronate dosage be altered when combined with high-frequency loading in osteoporosis treatment?
    Correa CB; Camargos GV; Chatterjee M; Mesquita MF; Del Bel Cury AA; Naert I; Duyck J; Vandamme K
    Osteoporos Int; 2017 Apr; 28(4):1287-1293. PubMed ID: 27921147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.
    Shiraki M; Nakamura T; Fukunaga M; Sone T; Usami A; Inoue T
    Curr Med Res Opin; 2012 Aug; 28(8):1357-67. PubMed ID: 22769235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
    Chen LX; Ning GZ; Zhou ZR; Li YL; Zhang D; Wu QL; Zhang TS; Cheng L; Feng SQ
    PLoS One; 2015; 10(4):e0123080. PubMed ID: 25881304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
    Hwang JS; Liou MJ; Ho C; Lin JD; Huang YY; Wang CJ; Tsai KS; Chen JF
    J Bone Miner Metab; 2010 May; 28(3):328-33. PubMed ID: 20012918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
    Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
    Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.